Sally A. Dominick
University of California, San Diego
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sally A. Dominick.
Cancer | 2015
Jessica R. Gorman; H. Irene Su; Samantha C. Roberts; Sally A. Dominick; Vanessa L. Malcarne
Young adult female cancer survivors have unmet reproductive concerns and informational needs that are associated with poorer quality of life. The purpose of this study was to examine the association between current reproductive concerns and moderate to severe depression among young survivors.
Psycho-oncology | 2014
Sally A. Dominick; Loki Natarajan; John P. Pierce; Hala Madanat; Lisa Madlensky
Lymphedema is a distressing and chronic condition affecting up to 30% of breast cancer survivors. Using a cross‐sectional study design, we examined the impact of self‐reported lymphedema‐related distress on psychosocial functioning among breast cancer survivors in the Womens Healthy Eating and Living Study. The Womens Healthy Eating and Living Study has a dataset that includes self‐report data on lymphedema status, symptoms, and distress.
Human Reproduction | 2016
Samantha C. Roberts; Susan M. Seav; Thomas W. McDade; Sally A. Dominick; Jessica R. Gorman; Brian W. Whitcomb; H.I. Su
STUDY QUESTION Are female young cancer survivors (YCS) able to self-collect high-quality dried blood spots (DBSs) at home to provide biospecimens for studying ovarian reserve? SUMMARY ANSWER YCS can self-collect high-quality DBS specimens in non-clinical settings, and anti-Mullerian hormone (AMH) levels can be assayed in such specimens. WHAT IS KNOWN ALREADY Large-scale biosample collection is a barrier to studying ovarian reserve in YCS. DBS collected by research personnel has high acceptability. AMH levels measured in DBS are highly correlated with those measured by serum-based methods. STUDY DESIGN, SIZE, DURATION In a prospective cohort study, YCS were recruited to self-collect DBS samples. AMH levels were assayed in 112 samples. PARTICIPANTS/MATERIALS, SETTING, METHODS YCS participants, ages 18-44, were recruited from a nationwide longitudinal cohort and DBS collection materials were posted to them. AMH levels were assayed by the Ansh DBS AMH ELISA and compared according to participant characteristics. MAIN RESULTS AND THE ROLE OF CHANCE Among 163 potential participants, 123 (75%) were enrolled. Of those enrolled, 112 (91%) were able to complete DBS self-collection and submit mailed samples adequate for measuring AMH. Participants (mean age 31.6 [SD 5.5]) were 85% white, 87% college graduates and 46% reported higher income. Common cancer types were lymphoma and leukemia (34%), breast cancer (30%) and thyroid or skin cancer (8%). The geometric mean (95% confidence interval) AMH level in DBS samples was 0.24 ng/ml (0.16-0.36). In adjusted analysis, AMH levels for survivors of breast cancer (0.02 ng/ml [0.01-0.07]) or leukemia/lymphoma (0.03 ng/ml [0.01-0.08]) were lower than the levels in thyroid or skin cancer survivors (0.12 ng/ml [0.03-0.44]). Pelvic radiation remained associated with lower AMH levels (0.20 ng/ml [0.10-0.40] in unexposed versus 0.02 ng/ml [0.01-0.06] in exposed). Amenorrheic survivors had AMH levels (0.02 ng/ml [0.01-0.06]) that were lower than those of YCS with 7-9 (0.09 ng/ml [0.03-0.32]) or ≥10 (0.17 ng/ml [0.08-0.37]) menstrual periods in the past year. LIMITATIONS, REASONS FOR CAUTION The results are generalizable to a population of highly educated, higher income YCS. It is unclear how generalizable the results are to other populations. WIDER IMPLICATIONS OF THE FINDINGS Self-collected DBS is a patient-friendly and minimally invasive tool for studying ovarian reserve in geographically diverse populations. STUDY FUNDING/COMPETING INTERESTS Research related to the development of this paper was supported by the National Institutes of Health, grants UL1 RR024926 pilot and HD080952-02, and by the American Cancer Society MRSG-08-110-01-CCE. The authors report no competing interests.
Women's Midlife Health | 2015
Susan M. Seav; Sally A. Dominick; Boris Stepanyuk; Jessica R. Gorman; Diana T. Chingos; Jennifer L. Ehren; Michael L. Krychman; H. Irene Su
Female sexual dysfunction occurs frequently in midlife breast cancer survivors (BCS) and encompasses problems with sexual desire, interest, arousal, orgasm and genitopelvic pain. Although common, sexual problems are under-diagnosed and under-treated in BCS. The objective of this review was to assess primary studies that intervene on sexual dysfunction in BCS. In February 2015, PubMed, SCOPUS, CINAHL, COCHRANE and Web of Science databases were systematically searched for randomized controlled clinical trials (RCTs) of vaginal (lubricants, moisturizers, estrogens, dehydroepiandrosterone [DHEA], testosterone, vibrators, dilators), systemic (androgens, anti-depressants, flibanserin, ospemifene), physical therapy (physical activity, pelvic floor training), counseling and educational interventions on sexual function in BCS. Observational studies of vaginal interventions were also included due to the paucity of RCTs. The search yielded 1414 studies, 34 of which met inclusion criteria. Both interventions and outcomes, measured by 31 different sexual function scales, were heterogeneous, and therefore data were not pooled. The review found that regular and prolonged use of vaginal moisturizers was effective in improving vaginal dryness, dyspareunia, and sexual satisfaction. Educational and counseling interventions targeting sexual dysfunction showed consistent improvement in various aspects of sexual health. No consistent improvements in sexual health were observed with physical activity, transdermal testosterone or hot flash interventions. There was a lack of BCS-specific data on vaginal lubricants, vibrators, dilators, pelvic floor therapy, flibanserin or ospemifene. Overall, the quality of evidence for these studies was moderate to very low. Because each of the interventions with BCS data had limited efficacy, clinical trials to test novel interventions are needed to provide evidence-based clinical recommendations and improve sexual function in BCS.
Journal of Cancer Survivorship | 2013
Sally A. Dominick; Lisa Madlensky; Loki Natarajan; John P. Pierce
Supportive Care in Cancer | 2014
Sally A. Dominick; Loki Natarajan; John P. Pierce; Hala Madanat; Lisa Madlensky
Journal of Cancer Survivorship | 2014
Sally A. Dominick; Brian W. Whitcomb; Jessica R. Gorman; Jennifer E. Mersereau; K. Chung; H. Irene Su
Fertility and Sterility | 2014
Sally A. Dominick; Brian W. Whitcomb; M.R. McLean; J.M. Bouknight; H.I. Su
Fertility and Sterility | 2014
M.R. McLean; Sally A. Dominick; Brian W. Whitcomb; H.I. Su; J.M. Bouknight
PsycEXTRA Dataset | 2013
Jessica R. Gorman; H. Irene Su; Samantha C. Roberts; Sally A. Dominick; John P. Pierce; Vanessa L. Malcarne